Kaufmann WE, Reiss AL. Molecular and cellular genetics of fragile X syndrome. Am J Med Genet. 1999;88:11–24.
Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, et al. Advances in the treatment of fragile X syndrome. Pediatrics. 2009;123:378–90.
Boyle L, Kaufmann WE. The behavioral phenotype of FMR1 mutations. Am J Med Genet. 2010;154C:469–76.
Schaefer TL, Davenport MH, Erickson CA. Emerging pharmacologic treatment options for fragile X syndrome. Appl Clin Genet. 2015;8:75–93.
Hampson DR, Gholizadeh S, Pacey LKK. Pathways to drug development for autism spectrum disorders. Clin Pharmacol Ther. 2011;91:189–200.
Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013;34:508–22.
Davenport MH, Schaefer TL, Friedmann KJ, Fitzpatrick SE, Erickson CA. Pharmacotherapy for fragile X syndrome: progress to date. Drugs. 2016;76:431–45.
Mullard A. Fragile X disappointments upset autism ambitions. Nat Rev Drug Discov. 2015;14:151–3.
Berry-Kravis E, Des Portes V, Hagerman R, Jacquemont S, Charles P, Visootsak J, Brinkman M, Rerat K, Koumaras B, Zhu L, et al. Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials. Sci Transl Med. 2016;8:321ra325.
Wigham S, McConachie H. Systematic review of the properties of tools used to measure outcomes in anxiety intervention studies for children with autism spectrum disorders. PLoS One. 2014;9:e85268.
McConachie H, Parr JR, Glod M, Hanratty J, Livingstone N, Oono IP, Robalino S, Baird G, Beresford B, Charman T, et al. Systematic review of tools to measure outcomes for young children with autism spectrum disorder. Health Technol Assess. 2015;19:1–506.
Hanratty J, Livingstone N, Robalino S, Terwee CB, Glod M, Oono IP, Rodgers J, Macdonald G, McConachie H. Systematic review of the measurement properties of tools used to measure behaviour problems in young children with autism. PLoS One. 2015;10:e0144649.
Lecavalier L, Wood JJ, Halladay AK, Jones NE, Aman MG, Cook EH, Handen BL, King BH, Pearson DA, Hallett V, et al. Measuring anxiety as a treatment endpoint in youth with autism spectrum disorder. J Autism Dev Disord. 2013;44:1128–43.
Anagnostou E, Jones N, Huerta M, Halladay AK, Wang P, Scahill L, Horrigan JP, Kasari C, Lord C, Choi D, et al. Measuring social communication behaviors as a treatment endpoint in individuals with autism spectrum disorder. Autism. 2014;19:622–36.
Scahill L, Aman MG, Lecavalier L, Halladay AK, Bishop SL, Bodfish JW, Grondhuis S, Jones N, Horrigan JP, Cook EH, et al. Measuring repetitive behaviors as a treatment endpoint in youth with autism spectrum disorder. Autism. 2015;19:38–52.
Budimirovic DB, Kaufmann WE. What can we learn about autism from studying fragile X syndrome? Dev Neurosci. 2011;33:379–94.
Barnes KV, Coughlin FR, O’Leary HM, Bruck N, Bazin GA, Beinecke EB, Walco AC, Cantwell NG, Kaufmann WE. Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales. J Neurodev Disord. 2015;7:30.
Kaufmann WE, Cortell R, Kau AS, Bukelis I, Tierney E, Gray RM, Cox C, Capone GT, Stanard P. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet A. 2004;129A:225–34.
Budimirovic DB, Bukelis I, Cox C, Gray RM, Tierney E, Kaufmann WE. Autism spectrum disorder in fragile X syndrome: differential contribution of adaptive socialization and social withdrawal. Am J Med Genet A. 2006;140A:1814–26.
Abbeduto L, Kover S, McDuffie A. Handbook of child language research methods. 2012.
Berry-Kravis E, Doll E, Sterling A, Kover ST, Schroeder SM, Mathur S, Abbeduto L. Development of an expressive language sampling procedure in fragile X syndrome: a pilot study. J Dev Behav Pediatr. 2013;34:245–51.
Roid GH. Stanford-Binet intelligence scales. Itasca: Riverside Publishing; 2003.
Wechsler D, Coalson DL, Raiford SE. Wechsler adult intelligence scale-fourth-WAIS-IV. San Antonio: Pearson; 2008.
Wahlstrom D, Breaux KC, Zhu J, Weiss LG. The Wechsler preschool and primary scale of intelligence—third edition, the Wechsler Intelligence Scale for Children—fourth edition, and the Wechsler individual achievement test. In: Flanagan DP, Harrison PL, editors. Contemporary intellectual assessment: theories, tests, and issues. New York: Guilford Press; 2012. p. 224–8.
Wechsler D. Wechsler Intelligence Scale for Children—fifth edition (WISC-V). San Antonio: The Psychological Corporation; 2014.
Mullen EM. Mullen scales of early learning. Circle Pines: AGS; 1995.
Bayley N, Reuner G. Bayley scales of infant and toddler development: Bayley-III. San Antonio: Harcourt Assessment, Psych. Corporation; 2006.
Kaufmann WE, Capone GT, Clarke M, Budimirovic DB. Autism in genetic intellectual disability. In: Autism. Totowa: The Humana Press Inc; 2008. p. 81-108
Klaiman C, Quintin E-M, Jo B, Lightbody AA, Hazlett HC, Piven J, Hall SS, Reiss AL. Longitudinal profiles of adaptive behavior in fragile X syndrome. Pediatrics. 2014. doi: 10.1542/peds.2013-3990.
Sparrow SS, Cicchetti DV, Balla DA. Vineland Adaptive Behavior Scales: (Vineland II), survey interview form/caregiver rating form. 2005.
Sparrow S, Cicchetti D, Saulnier C. Vineland Adaptive Behavior Scales, third edition (Vineland-3). 2016.
Hessl D, Nguyen DV, Green C, Chavez A, Tassone F, Hagerman RJ, Senturk D, Schneider A, Lightbody A, Reiss AL, Hall S. A solution to limitations of cognitive testing in children with intellectual disabilities: the case of fragile X syndrome. J Neurodev Disord. 2009;1:33–45.
Sansone SM, Schneider A, Bickel E, Berry-Kravis E, Prescott C, Hessl D. Improving IQ measurement in intellectual disabilities using true deviation from population norms. J Neurodev Disord. 2014;6:16.
Quintin EM, Jo B, Hall SS, Bruno JL, Chromik LC, Raman MM, Lightbody AA, Martin A, Reiss AL. The cognitive developmental profile associated with fragile X syndrome: a longitudinal investigation of cognitive strengths and weaknesses through childhood and adolescence. Dev Psychopathol. 2016;28:1457–69.
Akshoomoff N, Newman E, Thompson WK, McCabe C, Bloss CS, Chang L, Amaral DG, Casey BJ, Ernst TM, Frazier JA, et al. The NIH toolbox cognition battery: results from a large normative developmental sample (PING). Neuropsychology. 2014;28:1–10.
Gershon RC, Wagster MV, Hendrie HC, Fox NA, Cook KF, Nowinski CJ. NIH toolbox for assessment of neurological and behavioral function. Neurology. 2013;80:S2–6.
Casaletto KB, Umlauf A, Beaumont J, Gershon R, Slotkin J, Akshoomoff N, Heaton RK. Demographically corrected normative standards for the English version of the NIH toolbox cognition battery. J Int Neuropsychol Soc. 2015;21:378–91.
Hessl D, Sansone SM, Berry-Kravis E, Riley K, Widaman KF, Abbeduto L, Schneider A, Coleman J, Oaklander D, Rhodes KC. The NIH toolbox cognitive battery for intellectual disabilities: three preliminary studies and future directions. J Neurodev Disord. 2016;8:35.
Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®). Washington: American Psychiatric Pub; 2013.
Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, Decle P, Potanos K, Cook E, Salt J, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006;16:525–40.
Perry A, Flanagan HE, Geier JD, Freeman NL. Brief report: the Vineland Adaptive Behavior Scales in young children with autism spectrum disorders at different cognitive levels. J Autism Dev Disord. 2009;39:1066–78.
Duker P, Driel S, Bercken J. Communication profiles of individuals with Down’s syndrome, Angelman syndrome and pervasive developmental disorder. J Intellect Disabil Res. 2002;46:35–40.
Fidler D, Hepburn S, Rogers S. Early learning and adaptive behaviour in toddlers with Down syndrome: evidence for an emerging behavioural phenotype? Down Syndrome Research and Practice. 2006;9:37–44.
Berry-Kravis E. A 6-week, randomized, multicenter, double-blind, parallel, flexed-and fixed-dose study of MDX (metadoxine extended-release; MG01CI) compared with placebo in adolescents and adults with fragile X syndrome. In: 62nd Annual Meeting. San Antonio: AACAP; 2015.
Wang P, Wang L, Rathmell B, Carpenter R, Hagerman R, Berry-Kravis E. Treatment of fragile X syndrome with STX209 (arbaclofen): open label extension experience. Toronto: IMFAR; 2012.
Berry-Kravis E, Visootsak J, Hagerman R, Budimirovic D, Kaufmann W, Bear M, Walton-Bowen K, Carpenter R, Wang P. Arbaclofen in fragile X syndrome: results of phase 3 trials. In: Ann Neurol. Hoboken: Wiley-Blackwell; 2014. p. S174.
McCary LM, Machlin L, Roberts JE. The development of adaptive behaviour in toddlers and preschoolers with fragile X versus autism. Int J Dev Disab. 2013;59:67–79.
Frolli A, Piscopo S, Conson M. Developmental changes in cognitive and behavioural functioning of adolescents with fragile‐X syndrome. J Intellect Disabil Res. 2015;59:613–21.
de Bildt A, Kraijer D, Sytema S, Minderaa R. The psychometric properties of the Vineland Adaptive Behavior Scales in children and adolescents with mental retardation. J Autism Dev Disord. 2005;35:53–62.
Woodcock RW, Mather N, McGrew KS. Woodcock–Johnson III tests of cognitive abilities examiner’s manual. Itasca: Riverside Publishing; 2001.
Woodcock RR, McGrew KS, Schrank FA. Woodcock-Johnson III normative update technical manual. Itasca: Riverside Publishing; 2007.
Kessels RPC, Van Zandvoort MJE, Postma A, Kappelle LJ, De Haan EHF. The Corsi block-tapping task: standardization and normative data. Appl Neuropsychol. 2000;7:252–8.
Randolph C. Repeatable battery for the assessment of neuropsychological status (RBANS). San Antonio: Psychological Corporation; 1998.
Berry-Kravis E, Sumis A, Kim OK, Lara R, Wuu J. Characterization of potential outcome measures for future clinical trials in fragile X syndrome. J Autism Dev Disord. 2008;38:1751–7.
Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr. 2008;29:293–302.
Galusha-Glasscock JM, Horton DK, Weiner MF, Cullum CM. Video teleconference administration of the repeatable battery for the assessment of neuropsychological status. Arch Clin Neuropsychol. 2016;31:8–11.
Wilding J, Cornish K, Munir F. Further delineation of the executive deficit in males with fragile-X syndrome. Neuropsychologia. 2002;40:1343–9.
Scerif G, Cornish K, Wilding J, Driver J, Karmiloff-Smith A. Delineation of early attentional control difficulties in fragile X syndrome: focus on neurocomputational changes. Neuropsychologia. 2007;45:1889–98.
Hooper SR, Hatton D, Sideris J, Sullivan K, Hammer J, Schaaf J, Mirrett P, Ornstein PA, Bailey Jr DP. Executive functions in young males with fragile X syndrome in comparison to mental age-matched controls: baseline findings from a longitudinal study. Neuropsychology. 2008;22:36–47.
Zimmermann P, Fimm B, Gondan M. Testbatterie zur aufmerksamkeitsprüfung für kinder:(KiTAP);[das schloß der geister]. Frankfurt: Psytest; 2002.
Konrad K, Gunther T, Hanisch C, Herpertz-Dahlmann B. Differential effects of methylphenidate on attentional functions in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43:191–8.
Knox A, Schneider A, Abucayan F, Hervey C, Tran C, Hessl D, Berry-Kravis E. Feasibility, reliability, and clinical validity of the test of attentional performance for children (KiTAP) in fragile X syndrome (FXS). J Neurodev Disord. 2012;4:2.
Neuren. Neuren’s trofinetide successful in proof of concept phase 2 clinical trial in fragile X syndrome, vol. 2016. 2015.
Alcobra P. Alcobra announces results from phase 2 clinical trial of MDX for fragile x syndrome. 2015.
Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function. Child Neuropsychol. 2000;6:235–8.
Abbeduto L, Brady N, Kover ST. Language development and fragile X syndrome: Profiles, syndrome‐specificity, and within‐syndrome differences. Ment Retard Dev Disabil Res Rev. 2007;13:36–46.
Dunn DM, Dunn LM. Peabody picture vocabulary test: manual. San Antonio: Pearson; 2007.
Williams KT. EVT-2: Expressive vocabulary test. San Antonio: Pearson Assessments; 2007.
Wiig EH, Secord W, Semel EM. CELF preschool 2: clinical evaluation of language fundamentals preschool. Pearson/PsychCorp; 2004.
Wiig E, Semel E, Secord W. Clinical evaluation of language fundamentals®—fifth edition (CELF®-5). San Antonio: Pearson/PsychCorp.; 2013.
Dollaghan C. Child meets word: “fast mapping” in preschool children. J Speech Hear Res. 1985;28:449–54.
McDuffie A, Kover ST, Hagerman R, Abbeduto L. Investigating word learning in fragile X syndrome: a fast-mapping study. J Autism Dev Disord. 2013;43:1676–91.
Benjamin DP, McDuffie AS, Thurman AJ, Kover ST, Mastergeorge AM, Hagerman RJ, Abbeduto L. Effect of speaker gaze on word learning in fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder. J Speech Lang Hear Res. 2015;58:383–95.
Thurman AJ, McDuffie A, Kover ST, Hagerman R, Channell MM, Mastergeorge A, Abbeduto L. Use of emotional cues for lexical learning: a comparison of autism spectrum disorder and fragile X syndrome. J Autism Dev Disord. 2015;45:1042–61.
Benjamin D, Mastergeorge A, McDuffie A, Kover S, Hagerman R, Abbeduto L. Effects of labeling and pointing on object gaze in boys with fragile X syndrome: an eye-tracking study. Res Dev Disabil. 2014;35:2658–72.
Kover ST, McDuffie A, Abbeduto L, Brown WT. Effects of sampling context on spontaneous expressive language in males with fragile X syndrome or Down syndrome. J Speech Lang Hear Res. 2012;55:1022–38.
Hall SS, Frank MC, Pusiol GT, Farzin F, Lightbody AA, Reiss AL. Quantifying naturalistic social gaze in fragile X syndrome using a novel eye tracking paradigm. Am J Med Genet B Neuropsychiatr Genet. 2015;168:564–72.
Constantino JN, Gruber CP. The Social Responsiveness Scale (SRS) manual. Los Angeles: Western Psychological Services; 2007.
Constantino JN, Todd RD. Genetic structure of reciprocal social behavior. Am J Psychiatry. 2000;157:2043–5.
Constantino JN, Gruber CP, Davis S, Hayes S, Passanante N, Przybeck T. The factor structure of autistic traits. J Child Psychol Psychiatry. 2004;45:719–26.
Bolte S, Poustka F, Constantino JN. Assessing autistic traits: cross-cultural validation of the Social Responsiveness Scale (SRS). Autism Res. 2008;1:354–63.
Duku E, Vaillancourt T, Szatmari P, Georgiades S, Zwaigenbaum L, Smith IM, Bryson S, Fombonne E, Mirenda P, Roberts W, et al. Investigating the measurement properties of the Social Responsiveness Scale in preschool children with autism spectrum disorders. J Autism Dev Disord. 2013;43:860–8.
Pine E, Luby J, Abbacchi A, Constantino JN. Quantitative assessment of autistic symptomatology in preschoolers. Autism. 2006;10:344–52.
Constantino JN, Abbacchi AM, Lavesser PD, Reed H, Givens L, Chiang L, Gray T, Gross M, Zhang Y, Todd RD. Developmental course of autistic social impairment in males. Dev Psychopathol. 2009;21:127–38.
Farzin F, Scaggs F, Hervey C, Berry-Kravis E, Hessl D. Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome. J Autism Dev Disord. 2011;41:1515–22.
Crawford H, Moss J, Anderson GM, Oliver C, McCleery JP. Implicit discrimination of basic facial expressions of positive/negative emotion in fragile X syndrome and autism spectrum disorder. Am J Intellect Dev Disabil. 2015;120:328–45.
Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013;34:147–55.
Sansone S, Berry-Kravis E, Crestodina C, McLennan Y, Hagerman R, Hessl D. The sensitivity of an eye tracking paradigm as an outcome measure in a fragile x syndrome targeted treatment clinical trial. In: San Diego, CA. 49th Gatlinburg Conference on Research and Theory in Intellectual Disabilities. 2016.
Turkstra LS, Abbeduto L, Meulenbroek P. Social cognition in adolescent girls with fragile x syndrome. Am J Intellect Dev Disabil. 2014;119:319–39.
Baron-Cohen S, Wheelwright S, Scahill V, Lawson J, Spong A. Are intuitive physics and intuitive psychology independent? A test with children with Asperger syndrome. J Dev Learn Disord. 2001;5:47–78.
Klusek J, Hunt AW, Mirrett PL, Hatton DD, Hooper SR, Roberts JE, Bailey DB. Reading and phonological skills in boys with fragile X syndrome. J Autism Dev Disord. 2015;45:1699–711.
Hall SS, Hammond JL, Hirt M, Reiss AL. A “learning platform” approach to outcome measurement in fragile X syndrome: a preliminary psychometric study. J Intellect Disabil Res. 2012;56:947–60.
Hall SS, Hustyi KM, Hammond JL, Hirt M, Reiss AL. Using discrete trial training to identify specific learning impairments in boys with fragile X syndrome. J Autism Dev Disord. 2014;44:1659–70.
Au J, Berkowitz-Sutherland L, Schneider A, Schweitzer JB, Hessl D, Hagerman R. A feasibility trial of Cogmed working memory training in fragile X syndrome. J Pediatr Genet. 2014;3:147–56.
McDuffie A, Machalicek W, Bullard L, Nelson S, Mello M, Tempero-Feigles R, Castignetti N, Abbeduto L. A spoken-language intervention for school-aged boys with fragile X syndrome. Am J Intellect Dev Disabil. 2016;121:236–65.
McDuffie A, Oakes A, Machalicek W, Ma M, Bullard L, Nelson S, Abbeduto L. Early language intervention using distance video-teleconferencing: a pilot study of young boys with fragile X syndrome and their mothers. Am J Speech Lang Pathol. 2016;25:46–66.
Loeb PA. ILS: Independent Living Scales manual. San Antonio: Psychological Corporation; 1996.
Hustyi KM, Hall SS, Quintin E-M, Chromik LC, Lightbody AA, Reiss AL. The relationship between autistic symptomatology and independent living skills in adolescents and young adults with fragile X syndrome. J Autism Dev Disord. 2015;45:1836–44.
Martin A, Quintin EM, Hall S, Reiss AL. The role of executive function in independent living skills in female adolescents and young adults with fragile X syndrome. Am J Intellect Dev Disabil. 2016;121:448–60.
Maenner MJ, Smith LE, Hong J, Makuch R, Greenberg JS, Mailick MR. Evaluation of an activities of daily living scale for adolescents and adults with developmental disabilities. Disabil Health J. 2013;6:8–17.
Smith LE, Hong J, Greenberg JS, Mailick MR. Change in the behavioral phenotype of adolescents and adults with FXS: role of the family environment. J Autism Dev Disord. 2016;46:1824–33.
Bruininks RH, Woodcock RW, Weatherman RE, Hill BK. Scales of Independent Behavior-Revised (SIB-R) Riverside. 1996.
Wheeler A, Raspa M, Bann C, Bishop E, Hessl D, Sacco P, Bailey Jr DB. Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome. Am J Med Genet A. 2014;164A:141–55.
Aman MG, Singh NN, Stewart AW, Field CJ. Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Defic. 1985;89:492–502.
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med. 2002;347:314–21.
Zarcone JR, Hellings JA, Crandall K, Reese RM, Marquis J, Fleming K, Shores R, Williams D, Schroeder SR. Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures. Am J Ment Retard. 2001;106:525–38.
Arnold LE, Vitiello B, McDougle C, Scahill L, Shah B, Gonzalez NM, Chuang S, Davies M, Hollway J, Aman MG, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry. 2003;42:1443–50.
McDougle CJ, Scahill L, McCracken JT, Aman MG, Tierney E, Arnold LE, Freeman BJ, Martin A, McGough JJ, Cronin P, et al. Research units on pediatric psychopharmacology (RUPP) autism network. Background and rationale for an initial controlled study of risperidone. Child Adolesc Psychiatr Clin N Am. 2000;9:201–24.
Erickson CA, Stigler KA, Wink LK, Mullett JE, Kohn A, Posey DJ, McDougle CJ. A prospective open-label study of aripiprazole in fragile X syndrome. Psychopharmacology (Berl). 2011;216:85–90.
Fung LK, Quintin EM, Haas BW, Reiss AL. Conceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndrome. Curr Opin Neurol. 2012;25:112–24.
Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, Berry-Kravis E, Lachiewicz A, Brown EC, Hessl D. Psychometric study of the Aberrant Behavior Checklist in fragile X syndrome and implications for targeted treatment. J Autism Dev Disord. 2012;42:1377–92.
Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012;4:152ra127.
Berry-Kravis E, Hagerman RJ, Visootsak J, Budimirovic DB, Kaufmann WE, Bear MF, Walton-Bowen K, Wang P, Carpenter RL. Arbaclofen in fragile X syndrome: results of phase 3 trials. J Neurodev Disord. 2016. (in press JNDD-D-16-00048R2).
Snape M, Horrigan J, Glass L, et al. Improving outcome measures for fragile X syndrome clinical trials: development of fragile X syndrome specific rating scales. In: Society for the Study of Behavioral Phenotypes New York City. 2014.
Rojahn J, Rowe EW, Sharber AC, Hastings R, Matson JL, Didden R, Kroes DB, Dumont EL. The behavior problems inventory-short form for individuals with intellectual disabilities: part I: development and provisional clinical reference data. J Intellect Disabil Res. 2012;56:527–45.
Rojahn J, Matson JL, Lott D, Esbensen AJ, Smalls Y. The behavior problems inventory: an instrument for the assessment of self-injury, stereotyped behavior, and aggression/destruction in individuals with developmental disabilities. J Autism Dev Disord. 2001;31:577–88.
Hessl D, Berry-Kravis E, Cordeiro L, Yuhas J, Ornitz EM, Campbell A, Chruscinski E, Hervey C, Long JM, Hagerman RJ. Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:545–53.
Bailey Jr DB, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A. 2008;146A:2060–9.
Reilly C, Senior J, Murtagh L. ASD, ADHD, mental health conditions and psychopharmacology in neurogenetic syndromes: parent survey. J Intellect Disabil Res. 2015;59:307–18.
DuPaul GJ, Anastopoulos AD, Power TJ, Reid R, Ikeda MJ, McGoey KE. Parent ratings of attention-deficit/hyperactivity disorder symptoms: factor structure and normative data. J Psychopathol Behav Assess. 1998;20:83–102.
Association AP. Diagnostic and statistical manual of mental disorders (DSM)—IVth edition. Washington DC: APA; 1994.
Zhang S, Faries DE, Vowles M, Michelson D. ADHD rating scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Methods Psychiatr Res. 2005;14:186–201.
Gilliam JE. Attention-deficit/hyperactivity disorder test: a method for identifying individuals with ADHD. Austin: Pro-ed; 1995.
Conners CK, Wells KC, Parker JD, Sitarenios G, Diamond JM, Powell JW. A new self-report scale for assessment of adolescent psychopathology: factor structure, reliability, validity, and diagnostic sensitivity. J Abnorm Child Psychol. 1997;25:487–97.
Chromik LC, Quintin EM, Lepage JF, Hustyi KM, Lightbody AA, Reiss AL. The influence of hyperactivity, impulsivity, and attention problems on social functioning in adolescents and young adults with fragile X syndrome. J Atten Disord. 2015. [Epub ahead of print].
Cornish K, Cole V, Longhi E, Karmiloff-Smith A, Scerif G. Mapping developmental trajectories of attention and working memory in fragile X syndrome: developmental freeze or developmental change? Dev Psychopathol. 2013;25:365–76.
Achenbach T, Rescorla L. Manual for the ASEBA school-age forms & profiles: an integrated system of multi-informant assessment Burlington, VT: University of Vermont. Burlington: Research Center for Children, Youth, & Families; 2001.
Achenbach TM. Manual for the child behavior checklist/4-18 and 1991 profile. Burlington: Department of Psychiatry, University of Vermont; 1991.
Nakamura BJ, Ebesutani C, Bernstein A, Chorpita BF. A psychometric analysis of the child behavior checklist DSM-oriented scales. J Psychopathol Behav Assess. 2009;31:178–89.
Grefer M, Flory K, Cornish K, Hatton D, Roberts J. The emergence and stability of attention deficit hyperactivity disorder in boys with fragile X syndrome. J Intellect Disabil Res. 2016;60:167–78.
Swanson JM, Sandman CA, Deutsch C, Baren M. Methylphenidate hydrochloride given with or before breakfast: I. Behavioral, cognitive, and electrophysiologic effects. Pediatrics. 1983;72:49–55.
Cordeiro L, Ballinger E, Hagerman R, Hessl D. Clinical assessment of DSM-IV anxiety disorders in fragile X syndrome: prevalence and characterization. J Neurodev Disord. 2011;3:57–67.
Esbensen AJ, Rojahn J, Aman MG, Ruedrich S. Reliability and validity of an assessment instrument for anxiety, depression, and mood among individuals with mental retardation. J Autism Dev Disord. 2003;33:617–29.
Group RAS. The Pediatric Anxiety Rating Scale (PARS): development and psychometric properties. J Am Acad Child Adolesc Psychiatry. 2002;41:1061–9.
Talisa VB, Boyle L, Crafa D, Kaufmann WE. Autism and anxiety in males with fragile X syndrome: an exploratory analysis of neurobehavioral profiles from a parent survey. Am J Med Genet A. 2014;164A:1198–203.
Tonnsen BL, Malone PS, Hatton DD, Roberts JE. Early negative affect predicts anxiety, not autism, in preschool boys with fragile X syndrome. J Abnorm Child Psychol. 2013;41:267–80.
Tonnsen BL, Cornish KM, Wheeler AC, Roberts JE. Maternal predictors of anxiety risk in young males with fragile X. Am J Med Genet B Neuropsychiatr Genet. 2014;165B:399–409.
Russo-Ponsaran NM, Yesensky J, Hessl D, Berry-Kravis E. Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale-revised for fragile X syndrome. Am J Intellect Dev Disabil. 2014;119:1–16.
Khwaja OS, Ho E, Barnes KV, O’Leary HM, Pereira LM, Finkelstein Y, Nelson 3rd CA, Vogel-Farley V, DeGregorio G, Holm IA, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A. 2014;111:4596–601.
Budimirovic DB, Haas B, Blitz R, Esler A, Kaufmann WE, Sudhalter V, Stackhouse T, Berry-Kravis E. Consensus of the fragile X clinical and research consortium on clinical practices autism spectrum disorder in fragile X syndrome. Walnut Creek, California: National Fragile X Foundation Website; 2014.
Kaufmann WE, Kidd SA, Andrews H, Budimirovic DB, Esler A, Haas B, Stackhouse T, Peacock G, Riley C, Sherman SL, et al. Autism spectrum disorder in fragile X syndrome: characterization using the fragile X online registry with accessible research database (FORWARD). Pediatrics. 2015. (in press).
Mayes SD, Calhoun SL. Analysis of WISC-III, Stanford-Binet: IV, and academic achievement test scores in children with autism. J Autism Dev Disord. 2003;33:329–41.
Mayes SD, Calhoun SL. Ability profiles in children with autism: influence of age and IQ. Autism. 2003;7:65–80.
Hernandez RN, Feinberg RL, Vaurio R, Passanante NM, Thompson RE, Kaufmann WE. Autism spectrum disorder in fragile X syndrome: a longitudinal evaluation. Am J Med Genet A. 2009;149A:1125–37.
Hartley SL, Wheeler AC, Mailick MR, Raspa M, Mihaila I, Bishop E, Bailey DB. Autism symptoms across adulthood in men with fragile X syndrome: a cross-sectional analysis. J Autism Dev Disord. 2015;45:3668–79.
Hatton DD, Sideris J, Skinner M, Mankowski J, Bailey Jr DB, Roberts J, Mirrett P. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A. 2006;140A:1804–13.
Lord C, Risi S, Lambrecht L, Cook Jr EH, Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30:205–23.
Gotham K, Pickles A, Lord C. Standardizing ADOS scores for a measure of severity in autism spectrum disorders. J Autism Dev Disord. 2009;39:693–705.
Dawson G, Rogers S, Munson J, Smith M, Winter J, Greenson J, Donaldson A, Varley J. Randomized, controlled trial of an intervention for toddlers with autism: the Early Start Denver Model. Pediatrics. 2010;125:e17–23.
Green J, Charman T, McConachie H, Aldred C, Slonims V, Howlin P, Le Couteur A, Leadbitter K, Hudry K, Byford S, et al. Parent-mediated communication-focused treatment in children with autism (PACT): a randomised controlled trial. Lancet. 2010;375:2152–60.
de Bildt A, Oosterling IJ, van Lang ND, Sytema S, Minderaa RB, van Engeland H, Roos S, Buitelaar JK, van der Gaag R-J, de Jonge MV. Standardized ADOS scores: measuring severity of autism spectrum disorders in a Dutch sample. J Autism Dev Disord. 2011;41:311–9.
Shumway S, Farmer C, Thurm A, Joseph L, Black D, Golden C. The ADOS calibrated severity score: relationship to phenotypic variables and stability over time. Autism Res. 2012;5:267–76.
Lord C, Risi S, DiLavore PS, Shulman C, Thurm A, Pickles A. Autism from 2 to 9 years of age. Arch Gen Psychiatry. 2006;63:694–701.
Kamp-Becker I, Ghahreman M, Smidt J, Remschmidt H. Dimensional structure of the autism phenotype: relations between early development and current presentation. J Autism Dev Disord. 2009;39:557–71.
Luyster R, Gotham K, Guthrie W, Coffing M, Petrak R, Pierce K, Bishop S, Esler A, Hus V, Oti R, et al. The autism diagnostic observation schedule-toddler module: a new module of a standardized diagnostic measure for autism spectrum disorders. J Autism Dev Disord. 2009;39:1305–20.
Chawarska K, Klin A, Paul R, Volkmar F. Autism spectrum disorder in the second year: stability and change in syndrome expression. J Child Psychol Psychiatry. 2007;48:128–38.
Gray K, Tonge B, Sweeney D, Einfeld S. Screening for autism in young children with developmental delay: an evaluation of the developmental behaviour checklist: early screen. J Autism Dev Disord. 2008;38:1003–10.
Norris M, Lecavalier L, Edwards MC. The structure of autism symptoms as measured by the autism diagnostic observation schedule. J Autism Dev Disord. 2012;42:1075–86.
Erickson CA, Wink LK, Ray B, Early MC, Stiegelmeyer E, Mathieu-Frasier L, Patrick V, Lahiri DK, McDougle CJ. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013;228:75–84.
Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord. 1980;10:91–103.
Schopler E, Reichler RJ, Renner BR. Child autism rating scale. Los Angeles: Western Psychological Services Corporation; 1988.
Schopler E, Van Bourgondien ME, Wellman GJ, Love SR. CARS 2: Childhood Autism Rating Scale. 2010.
Charman T, Howlin P, Berry B, Prince E. Measuring developmental progress of children with autism spectrum disorder on school entry using parent report. Autism. 2004;8:89–100.
Russell PS, Daniel A, Russell S, Mammen P, Abel JS, Raj LE, Shankar SR, Thomas N. Diagnostic accuracy, reliability and validity of Childhood Autism Rating Scale in India. World J Pediatr. 2010;6:141–7.
Stella J, Mundy P, Tuchman R. Social and nonsocial factors in the Childhood Autism Rating Scale. J Autism Dev Disord. 1999;29:307–17.
Magyar CI, Pandolfi V. Factor structure evaluation of the Childhood Autism Rating Scale. J Autism Dev Disord. 2007;37:1787–94.
Berument SK, Rutter M, Lord C, Pickles A, Bailey A. Autism screening questionnaire: diagnostic validity. Br J Psychiatry. 1999;175:444–51.
Lord C, Rutter M, Le Couteur A. Autism diagnostic interview-revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659–85.
Cochran L, Moss J, Nelson L, Oliver C. Contrasting age related changes in autism spectrum disorder phenomenology in Cornelia de Lange, fragile X, and Cri du Chat syndromes: results from a 2.5 year follow‐up. In: American Journal of Medical Genetics Part C: Seminars in Medical Genetics. Hoboken: John Wiley & Sons, Inc; 2015. p. 188–197.
Hall SS, Lightbody AA, Hirt M, Rezvani A, Reiss AL. Autism in fragile X syndrome: a category mistake? J Am Acad Child Adolesc Psychiatry. 2010;49:921–33.
Moss J, Oliver C, Nelson L, Richards C, Hall S. Delineating the profile of autism spectrum disorder characteristics in Cornelia de Lange and fragile X syndromes. Am J Intellect Dev Disabil. 2013;118:55–73.
Waite J, Moss J, Beck SR, Richards C, Nelson L, Arron K, Burbidge C, Berg K, Oliver C. Repetitive behavior in Rubinstein–Taybi syndrome: parallels with autism spectrum phenomenology. J Autism Dev Disord. 2015;45:1238–53.
Snow AV, Lecavalier L. Sensitivity and specificity of the modified checklist for autism in toddlers and the social communication questionnaire in preschoolers suspected of having pervasive developmental disorders. Autism. 2008;12:627–44.
Magyar CI, Pandolfi V, Dill CA. An initial evaluation of the social communication questionnaire for the assessment of autism spectrum disorders in children with Down syndrome. J Dev Behav Pediatr. 2012;33:134–45.
Turner M. Annotation: repetitive behaviour in autism: a review of psychological research. J Child Psychol Psychiatry. 1999;40:839–49.
Bishop SL, Richler J, Lord C. Association between restricted and repetitive behaviors and nonverbal IQ in children with autism spectrum disorders. Child Neuropsychol. 2006;12:247–67.
Richler J, Huerta M, Bishop SL, Lord C. Developmental trajectories of restricted and repetitive behaviors and interests in children with autism spectrum disorders. Dev Psychopathol. 2010;22:55–69.
Green VA, Sigafoos J, Pituch KA, Itchon J, O’Reilly M, Lancioni GE. Assessing behavioral flexibility in individuals with developmental disabilities. Focus Autism Other Dev Disabl. 2006;21:230–6.
Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord. 2000;30:237–43.
Lam KS, Bodfish JW, Piven J. Evidence for three subtypes of repetitive behavior in autism that differ in familiality and association with other symptoms. J Child Psychol Psychiatry. 2008;49:1193–200.
Lam KS, Aman MG. The repetitive behavior scale-revised: independent validation in individuals with autism spectrum disorders. J Autism Dev Disord. 2007;37:855–66.
Mirenda P, Smith IM, Vaillancourt T, Georgiades S, Duku E, Szatmari P, Bryson S, Fombonne E, Roberts W, Volden J. Validating the repetitive behavior scale-revised in young children with autism spectrum disorder. J Autism Dev Disord. 2010;40:1521–30.
Bishop SL, Hus V, Duncan A, Huerta M, Gotham K, Pickles A, Kreiger A, Buja A, Lund S, Lord C. Subcategories of restricted and repetitive behaviors in children with autism spectrum disorders. J Autism Dev Disord. 2013;43:1287–97.
Harrop C, McConachie H, Emsley R, Leadbitter K, Green J, Consortium P. Restricted and repetitive behaviors in autism spectrum disorders and typical development: cross-sectional and longitudinal comparisons. J Autism Dev Disord. 2014;44:1207–19.
Brock M, Hatton D. Distinguishing features of autism in boys with fragile X syndrome. J Intellect Disabil Res. 2010;54:894–905.
Wolff JJ, Bodfish JW, Hazlett HC, Lightbody AA, Reiss AL, Piven J. Evidence of a distinct behavioral phenotype in young boys with fragile X syndrome and autism. J Am Acad Child Adolesc Psychiatry. 2012;51:1324–32.
Wolff JJ, Hazlett HC, Lightbody AA, Reiss AL, Piven J. Repetitive and self-injurious behaviors: associations with caudate volume in autism and fragile X syndrome. J Neurodev Disord. 2013;5:1.
Lewis M, Kim SJ. The pathophysiology of restricted repetitive behavior. J Neurodev Disord. 2009;1:114–32.
Moss J, Oliver C, Arron K, Burbidge C, Berg K. The prevalence and phenomenology of repetitive behavior in genetic syndromes. J Autism Dev Disord. 2009;39:572–88.
Edwards MJ, Lang AE, Bhatia KP. Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord. 2012;27:179–85.
Sudhalter V, Cohen IL, Silverman W, Wolf-Schein EG. Conversational analyses of males with fragile X, Down syndrome, and autism: comparison of the emergence of deviant language. Am J Ment Retard. 1990;94(4):431–41.
Roberts JE, Chapman RS, Warren SF, Brookes PH. Language of preschool and school-age children with Down syndrome and fragile X syndrome. In: Roberts JE, Chapman RS, Warren SF, editors. Speech and language development and intervention in Down syndrome and Fragile X syndrome. Baltimore: Brookes Pub; 2008
Hagerman RJ. The physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research. Baltimore: Johns Hopkins University Press; 2002.
Oakes A, Thurman A, McDuffie A, Bullard L, Hagerman R, Abbeduto L. Characterising repetitive behaviours in young boys with fragile X syndrome. J Intellect Disabil Res. 2016;60:54–67.
Rojahn J. Self-injurious and stereotypic behavior of noninstitutionalized mentally retarded people: prevalence and classification. Am J Ment Defic. 1986;30:49–57.
Bartak L, Rutter M. Differences between mentally retarded and normally intelligent autistic children. J Autism Child Schizophr. 1976;6:109–20.
Valenza G, Nardelli M, Lanata A, Gentili C, Bertschy G, Paradiso R, Scilingo EP. Wearable monitoring for mood recognition in bipolar disorder based on history-dependent long-term heart rate variability analysis. IEEE J Biomed Health Inform. 2014;18:1625–35.
Bakker D, Kazantzis N, Rickwood D, Rickard N. Mental health smartphone apps: review and evidence-based recommendations for future developments. JMIR Mental Health. 2016;3(1):e7.
Weng N, Weiler IJ, Sumis A, Berry‐Kravis E, Greenough WT. Early‐phase ERK activation as a biomarker for metabolic status in fragile X syndrome. Am J Med Genet B Neuropsychiatr Genet. 2008;147:1253–7.
Erickson CA, Weng N, Weiler IJ, Greenough WT, Stigler KA, Wink LK, McDougle CJ. Open-label riluzole in fragile X syndrome. Brain Res. 2011;1380:264–70.
Berridge MJ. Inositol trisphosphate and calcium signalling. Nature. 1993;361:315–25.
Doble A. The pharmacology and mechanism of action of riluzole. Neurology. 1996;47:233S–41.
Pellerin D, Çaku A, Fradet M, Bouvier P, Dubé J, Corbin F. Lovastatin corrects ERK pathway hyperactivation in fragile X syndrome: potential of platelet’s signaling cascades as new outcome measures in clinical trials. Biomarkers. 2016;21(6):497–508.
Castrén M, Lampinen KE, Miettinen R, Koponen E, Sipola I, Bakker CE, Oostra BA, Castrén E. BDNF regulates the expression of fragile X mental retardation protein mRNA in the hippocampus. Neurobiol Dis. 2002;11:221–9.
Lauterborn JC, Rex CS, Kramár E, Chen LY, Pandyarajan V, Lynch G, Gall CM. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. In: The Journal of Neuroscience, vol. 27. 2007. p. 10685–94.
Uutela M, Lindholm J, Louhivuori V, Wei H, Louhivuori L, Pertovaara A, Åkerman K, Castrén E, Castrén M. Reduction of BDNF expression in Fmr1 knockout mice worsens cognitive deficits but improves hyperactivity and sensorimotor deficits. Genes Brain Behav. 2012;11:513–23.
Kiefer F, Mann K. Acamprosate: how, where, and for whom does it work? Mechanism of action, treatment targets, and individualized therapy. Curr Pharm Des. 2010;16:2098–102.
Makkonen I, Riikonen R, Kuikka JT, Kokki H, Bressler JP, Marshall C, Kaufmann WE. Brain derived neurotrophic factor and serotonin transporter binding as markers of clinical response to fluoxetine therapy in children with autism. J Pediatr Neurol. 2011;9:1–8.
Lahiri DK, Sokol DK, Erickson C, Ray B, Ho CY, Maloney B. Autism as early neurodevelopmental disorder: evidence for an sAPPα-mediated anabolic pathway. Front Cell Neurosci. 2013;7:94.
De Rubeis S, Bagni C. Fragile X mental retardation protein control of neuronal mRNA metabolism: insights into mRNA stability. Mol Cell Neurosci. 2010;43:43–50.
Westmark CJ, Malter JS. FMRP mediates mGluR 5-dependent translation of amyloid precursor protein. PLoS Biol. 2007;5:e52.
Theoharides TC, Stewart JM, Panagiotidou S, Melamed I. Mast cells, brain inflammation and autism. Eur J Pharmacol. 2016;778:96–102.
Theoharides T, Tsilioni I, Patel A, Doyle R. Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders. Transl Psychiatry. 2016;6:e844.
Gu F, Chauhan V, Chauhan A. Glutathione redox imbalance in brain disorders. Curr Opin Clin Nutr Metab Care. 2015;18:89–95.
Muller C, Anacker A, Veenstra-VanderWeele J. The serotonin system in autism spectrum disorder: from biomarker to animal models. Neuroscience. 2016;321:24–41.
Farzin F, Rivera SM, Hessl D. Brief report: visual processing of faces in individuals with fragile X syndrome: an eye tracking study. J Autism Dev Disord. 2009;39:946–52.
Niedermeyer E, da Silva FHL. Electroencephalography: basic principles, clinical applications, and related fields. Philadelphia: Lippincott Williams & Wilkins; 2005.
Pizzagalli DA. Electroencephalography and high-density electrophysiological source localization. Handbook of psychophysiology. 2007;3:56–84.
Van der Molen M, Van der Molen M, Ridderinkhof K, Hamel B, Curfs L, Ramakers G. Auditory change detection in fragile X syndrome males: a brain potential study. Clin Neurophysiol. 2012;123:1309–18.
Miller LJ, McIntosh D, McGrath J, Shyu V, Lampe M, Taylor A, Tassone F, Neitzel K, Stackhouse T, Hagerman RJ. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome. Am J Med Genet. 1999;83:268–79.
Galvez R, Gopal AR, Greenough WT. Somatosensory cortical barrel dendritic abnormalities in a mouse model of the fragile X mental retardation syndrome. Brain Res. 2003;971:83–9.
Rotschafer S, Razak K. Altered auditory processing in a mouse model of fragile X syndrome. Brain Res. 2013;1506:12–24.
Gandal MJ, Edgar JC, Ehrlichman RS, Mehta M, Roberts TP, Siegel SJ. Validating γ oscillations and delayed auditory responses as translational biomarkers of autism. Biol Psychiatry. 2010;68:1100–6.
Harvey B, Siok C, Kiss T, Volfson D, Grimwood S, Shaffer C, Hajós M. Neurophysiological signals as potential translatable biomarkers for modulation of metabotropic glutamate 5 receptors. Neuropharmacology. 2013;75:19–30.
Roberts TP, Cannon KM, Tavabi K, Blaskey L, Khan SY, Monroe JF, Qasmieh S, Levy SE, Edgar JC. Auditory magnetic mismatch field latency: a biomarker for language impairment in autism. Biol Psychiatry. 2011;70:263–9.
Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet. 2009;46:266–71.
Schneider A, Leigh MJ, Adams P, Nanakul R, Chechi T, Olichney J, Hagerman R, Hessl D. Electrocortical changes associated with minocycline treatment in fragile X syndrome. J Psychopharmacol. 2013;27:956–63.
Yang J-C, Niu Y-Q, Simon C, Seritan AL, Chen L, Schneider A, Moghaddam ST, Hagerman PJ, Hagerman RJ, Olichney JM. Memantine effects on verbal memory in fragile X-associated tremor/ataxia syndrome (FXTAS): a double-blind brain potential study. Neuropsychopharmacology. 2014;39:2760–8.
Gross C, Hoffmann A, Bassell GJ, Berry-Kravis EM. Therapeutic strategies in fragile X syndrome: from bench to bedside and back. Neurotherapeutics. 2015;12:584–608.
Ethridge L, White S, Mosconi M, Wang J, Byerly M, Sweeney J. Reduced habituation of auditory evoked potentials indicate cortical hyper-excitability in fragile X syndrome. Transl Psychiatry. 2016;6:e787.
Dunn W. Sensory profile 2 manual. San Antonio: Pearson; 2014.
Van Hecke AV, Stevens S, Carson AM, Karst JS, Dolan B, Schohl K, McKindles RJ, Remmel R, Brockman S. Measuring the plasticity of social approach: a randomized controlled trial of the effects of the PEERS intervention on EEG asymmetry in adolescents with autism spectrum disorders. J Autism Dev Disord. 2015;45:316–35.
Wang Y, Sokhadze EM, El-Baz AS, Li X, Sears L, Casanova MF, Tasman A. Relative power of specific EEG bands and their ratios during neurofeedback training in children with autism spectrum disorder. Front Hum Neurosci. 2015;9.
Mueller S, Schuff N, Weiner M. Evaluation of treatment effects in Alzheimer’s and other neurodegenerative diseases by MRI and MRS. NMR Biomed. 2006;19:655–68.
Fung LK, Reiss AL. Moving toward integrative, multidimensional research in modern psychiatry: lessons learned from fragile X syndrome. Biol Psychiatry. 2016;80(2):100–11.
Brown TT, Kuperman JM, Chung Y, Erhart M, McCabe C, Hagler DJ, Venkatraman VK, Akshoomoff N, Amaral DG, Bloss CS. Neuroanatomical assessment of biological maturity. Curr Biol. 2012;22:1693–8.
Roberto CA, Mayer LE, Brickman AM, Barnes A, Muraskin J, Yeung LK, Steffener J, Sy M, Hirsch J, Stern Y. Brain tissue volume changes following weight gain in adults with anorexia nervosa. Int J Eat Disord. 2011;44:406–11.
Eijk J, Demirakca T, Frischknecht U, Hermann D, Mann K, Ende G. Rapid partial regeneration of brain volume during the first 14 days of abstinence from alcohol. Alcohol Clin Exp Res. 2013;37:67–74.
Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry. 2005;58:62–6.
Arnone D, McKie S, Elliott R, Juhasz G, Thomas E, Downey D, Williams S, Deakin J, Anderson I. State-dependent changes in hippocampal grey matter in depression. Mol Psychiatry. 2013;18:1265–72.
Ibrahim I, Tintera J, Skoch A, Jirů F, Hlustik P, Martinkova P, Zvara K, Rasova K. Fractional anisotropy and mean diffusivity in the corpus callosum of patients with multiple sclerosis: the effect of physiotherapy. Neuroradiology. 2011;53:917–26.
Wang T, Huang X, Huang P, Li D, Lv F, Zhang Y, Zhou L, Yang D, Xie P. Early-stage psychotherapy produces elevated frontal white matter integrity in adult major depressive disorder. PLoS One. 2013;8:e63081.
Fan Q, Yan X, Wang J, Chen Y, Wang X, Li C, Tan L, You C, Zhang T, Zuo S. Abnormalities of white matter microstructure in unmedicated obsessive-compulsive disorder and changes after medication. PLoS One. 2012;7:e35889.
Matthews PM, Honey GD, Bullmore ET. Applications of fMRI in translational medicine and clinical practice. Nat Rev Neurosci. 2006;7:732–44.
Chapin H, Bagarinao E, Mackey S. Real-time fMRI applied to pain management. Neurosci Lett. 2012;520:174–81.
Singh MK, Chang KD. The neural effects of psychotropic medications in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2012;21:753–71.
Beauregard M. Functional neuroimaging studies of the effects of psychotherapy. Dialogues Clin Neurosci. 2014;16:75.
Lukas SE. New perspectives on using brain imaging to study CNS stimulants. Neuropharmacology. 2014;87:104–14.
Gudayol-Ferré E, Peró-Cebollero M, González-Garrido AA, Guàrdia-Olmos J. Changes in brain connectivity related to the treatment of depression measured through fMRI: a systematic review. Front Hum Neurosci. 2015;9:582.
Reid LB, Boyd RN, Cunnington R, Rose SE. Interpreting intervention induced neuroplasticity with fMRI: the case for multimodal imaging strategies. Neural Plast. 2015;2016:1–13.
Strangman G, Culver JP, Thompson JH, Boas DA. A quantitative comparison of simultaneous BOLD fMRI and NIRS recordings during functional brain activation. Neuroimage. 2002;17:719–31.
Obrig H. NIRS in clinical neurology—a “promising”tool? Neuroimage. 2014;85:535–46.
Cutini S, Brigadoi S. Unleashing the future potential of functional near-infrared spectroscopy in brain sciences. J Neurosci Methods. 2014;232:152–6.
Birbaumer N, Murguialday AR, Cohen L. Brain-computer interface in paralysis. Curr Opin Neurol. 2008;21:634–8.
Kober SE, Wood G, Kurzmann J, Friedrich EV, Stangl M, Wippel T, Väljamäe A, Neuper C. Near-infrared spectroscopy based neurofeedback training increases specific motor imagery related cortical activation compared to sham feedback. Biol Psychol. 2014;95:21–30.
Tartaglia N, Cordeiro L, McGrew J, Stackhouse T. Neuromotor outcome measures for clinical trials in fragile x syndrome. In: 13th International Fragile X Conference. Miami, FL. 2012.
Raspa M, Sacco P, Candrilli S, Bishop E, Petrillo J. Validity of a condition specific outcome measure for fragile X syndrome: the Aberrant Behaviour Checklist‐utility index. J Intellect Disabil Res. 2016;60(9):844–55.
Kerr C, Breheny K, Lloyd A, Brazier J, Bailey Jr DB, Berry-Kravis E, Cohen J, Petrillo J. Developing a utility index for the Aberrant Behavior Checklist (ABC-C) for fragile X syndrome. Qual Life Res. 2015;24:305–14.
Budimirovic DB, Duy PQ. Challenges in translating therapeutic frontiers in clinical trials: where are we now and what’s next. Madridge J Neuro Sci. 2016;1:e1–3.
Jeste SS, Geschwind DH. Clinical trials for neurodevelopmental disorders: at a therapeutic frontier. Sci Transl Med. 2016;8:321fs321.
Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011;3:64ra61.
Greiss-Hess L, Hagerman RJ. Effects of sertraline treatment for young children with fragile X syndrome: examination of developmental outcomes and family contexts. Dissertation Abstracts International Section A: Humanities and Social Sciences. U California, Davis. 2015.
Hall SS, Lightbody AA, McCarthy BE, Parker KJ, Reiss AL. Effects of intranasal oxytocin on social anxiety in males with fragile X syndrome. Psychoneuroendocrinology. 2012;37:509–18.
de Diego-Otero Y, Calvo-Medina R, Quintero-Navarro C, Sánchez-Salido L, García-Guirado F, del Arco-Herrera I, Fernández-Carvajal I, Ferrando-Lucas T, Caballero-Andaluz R, Pérez-Costillas L. A combination of ascorbic acid and α-tocopherol to test the effectiveness and safety in the fragile X syndrome: study protocol for a phase II, randomized, placebo-controlled trial. Trials. 2014;15:1.
Wirojanan J, Jacquemont S, Diaz R, Bacalman S, Anders TF, Hagerman RJ, Goodlin-Jones BL. The efficacy of melatonin for sleep problems in children with autism, fragile X syndrome, or autism and fragile X syndrome. J Clin Sleep Med. 2009;5:145–50.
Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, et al. A double-blind, parallel, multicenter comparison ofL-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet. 2008;146A:803–12.
Hagerman RJ, Murphy MA, Wittenberger MD. A controlled trial of stimulant medication in children with the fragile X syndrome. Am J Med Genet. 1988;30:377–92.
Budimirovic D, Phan D. Neurobehavioral features and targeted treatments in fragile X syndrome: current insights and future directions. Engrams. 2015;37:5–19.
Hoeffer CA, Sanchez E, Hagerman RJ, Mu Y, Nguyen DV, Wong H, Whelan AM, Zukin RS, Klann E, Tassone F. Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome. Genes Brain Behav. 2012;11:332–41.
Kesler SR, Lightbody AA, Reiss AL. Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study. Am J Med Genet A. 2009;149A:403–7.